Lentiviral vectors are efficient tools for introducing genes into nondividing as well as dividing cells \[[@B1],[@B2]\]. The most widely used lentiviral vectors are based on HIV but have been extensively modified to achieve high virus titers and decrease the risk of producing replication-competent virus \[[@B3]--[@B11]\]. To maximize expression of vector RNAs in virus-producing cells, most lentiviral vectors employ a chimeric promoter containing a strong RNA pol II promoter that initiates transcription at the first base of the long-terminal repeat (LTR) 'R' element. To improve biosafety, lentiviral vectors retain all *cis*-acting sequences needed for viral RNA packaging, reverse transcription and proviral DNA integration, yet remove all HIV protein-coding genes. HIV genes that are needed to produce infectious but nonreplication-competent virus are expressed separately, in *trans*, in lentiviral packaging cells \[[@B2]\].

Differences in lentiviral vectors and packaging systems can markedly affect virus production. For example, among the nine HIV protein-encoding genes, a widely used third-generation viral packaging system provides only *gag*, *pol*, *rev* and the VSV-G membrane fusogen, whereas the preceding second-generation system also expresses *tat* \[[@B4],[@B5]\]. Tat protein is required for expression of lentiviral vectors that use the HIV LTR promoter but is not essential for Tat-independent chimeric promoters such as the immediate-early Cytomegalovirus (CMV) or Rous Sarcoma Virus (RSV) promoters \[[@B4],[@B8]\]. However, Tat may increase vector expression by enabling transcriptional elongation through the TAR element in the 'R' component of the HIV 5′ LTR \[[@B12],[@B13]\].

pLKO.1 is one of the most widely used lentiviral vectors for shRNA expression due to its transduction efficacy, low levels of recombination, high-level shRNA expression and use in shRNA libraries \[[@B14]\]. As a third-generation self-inactivating lentiviral vector, pLKO.1 contains a hybrid RSV promoter and HIV 5′ LTR and is amenable to both second- and third-generation packaging. However, at previously defined packaging vector ratios, pLKO.1 produces lower titers using the third-generation packaging system compared with the second-generation system. Since lentiviral vectors containing the hybrid CMV-HIV promoter often yield high lentiviral vector expression \[[@B15],[@B16]\], we examined whether substituting the CMV promoter for the pLKO.1 RSV promoter could improve viral titer.

First, we cloned the CMV promoter from MA1 \[[@B16]; originally derived from pCCL.sin.cPPT.PGK.GFP.WPRE \[[@B7]\]\] into pLKO.1 \[[@B14]; Addgene\] or into various pLKO.1 derivatives to generate pLKO.1C vectors ([Figure 1](#F1){ref-type="fig"}A & B).

![Improved transduction efficiency by pLKO.1C and third-generation lentiviral packaging.\
**(A & B)** pLKO.1C cloning strategy. pLKO.1 and MA1 vectors were digested with AflIII and MfeI, and the 5.7-kb pLKO.1 vector and 1.8-kb CMV fragments were extracted and ligated. **(C)** Ratios of second- or third-generation lentiviral packaging plasmids for comparison of pLKO.1 versus pLKO.1C or pLKO.1-YFP versus pLKO.1C-YFP virus production. 293T cells were transfected with each ratio of lentiviral packaging plasmids and viruses were harvested after 60 h. **(D)** DAOY cells transduced with pLKO.1 or pLKO.1C virus generated from the indicated viral packaging components and ratios in the presence of 4 μg/ml polybrene (Sigma-Aldrich), selected in 2 µg/ml puromycin and stained with crystal violet (Sigma--Aldrich) after 4 days. **(E)** DAOY cells transduced with virus carrying either sh*SCR* (*left*) or sh*RB1-733* (*right*) generated with pLKO.1-YFP- or pLKO.1C-YFP-based vectors, with the viral packaging components and ratios shown in (C), followed by FACS to define the transforming units (TU) per ml of producer cell supernatant. n = 2 per group. Unpaired *t-*test. Experiments were performed at least twice with similar results.\
\*\*p \< 0.02; \*\*\*p \< 0.01.\
CMV: Cytomegalovirus; YFP: Yellow fluorescent protein.](btn-68-349-g1){#F1}

To test the activity of each promoter and packing system, we produced virus by reverse transfection of 293T cells using the indicated vector and packaging constructs as described \[[@B17]\]. For each 15-cm dish, a total of 50 μg of plasmid DNA was used for the transfection for second-generation packaging (20 μg pLKO-based transfer vector, 20 μg pCMV-dR8.91, 10 μg pVSV-G), and 70 μg of total plasmid was used for third-generation packaging (20 μg pLKO-based transfer vector, 20 μg pMDLg/pRRE, 10 μg pVSV-G and 20 μg pRSV-Rev) ([Figure 1](#F1){ref-type="fig"}C). After 60 h, viral supernatants were harvested and concentrated 76-fold by centrifugation \[[@B17]\]; resuspended viruses were used to transduce cell lines in the presence of polybrene.

In initial tests, pLKO.1-sh*SCR* was produced using second- or third-generation packaging, whereas pLKO.1C-sh*SCR* was produced solely with the third-generation system ([Figure 1](#F1){ref-type="fig"}C). After transduction, DAOY cells were selected with puromycin for 4 days, fixed and stained with crystal violet to visualize puromycin-resistant colonies. This revealed that third-generation packaging of pLKO.1 yielded lower viral titers than second-generation packaging, whereas third-generation packaging of pLKO.1C yielded a qualitatively higher titer ([Figure 1](#F1){ref-type="fig"}D).

To titer the virus more accurately, we generated pLKO.1C-YFP by substituting the CMV for RSV promoter in pLKO.1 derivative pLKO.1-YFP \[[@B17]\]. DAOY cells were transduced with either pLKO.1-YFP (sh*SCR* and sh*RB1*-733) or the corresponding pLKO.1C-YFP vectors, and the titers calculated after counting yellow fluorescent protein (YFP)-positive cells by FACS. Similar to the previous result, pLKO.1-YFP constructs had reduced viral titer using third-generation versus second-generation packaging, whereas the CMV-driven pLKO.1C-YFP virus had more than three-times higher titer with the third-generation system ([Figure 1](#F1){ref-type="fig"}E).

Since different amounts of each lentiviral vector and packaging construct have been suggested \[[@B18]\], we compared different ratios of the four viral components to define the optimal conditions with pLKO.1C-sh*SCR* vectors ([Figure 2](#F2){ref-type="fig"}A). 293T cells were transfected with third-generation packaging constructs at four ratios (with 20 μg lenti shRNA vector per 15-cm dish), and 1--2% of harvested virus was used to monitor the transduction of DAOY cells by selection and crystal violet staining of puromycin-resistant cells. The highest titer was obtained using a 4:2:1:1 ratio of transfer vector plasmid (pLKO.1 or pLKO.1C), packaging plasmid (pMDLg/pRRE), VSV fusogen plasmid (pVSV-G), and pRSV-Rev plasmid, respectively ([Figure 2](#F2){ref-type="fig"}B). With these ratios, third-generation packaging of pLKO.1C vectors gave higher efficiency than the second-generation packaging system ([Figure 2](#F2){ref-type="fig"}C).

![Improved transduction by pLKO.1C at optimized viral component ratios.\
**(A)** Ratios of third-generation lentiviral packaging plasmids used for optimization. **(B)** DAOY cells transduced with 1 or 2% of total virus generated from different viral packaging ratios, puromycin-selected and visualized by crystal violet staining. **(C)** DAOY transduction with pLKO.1 (RSV) or pLKO.1C (CMV) versions of sh*SCR* or sh*RB1-733* lentivirus after second- or optimized third-generation packaging, followed by puromycin selection and crystal violet staining. **(D)** DAOY transduction with the indicated vectors and ratios. After 4 days, RNA was isolated, and qRT-PCR was performed to measure RB knockdown efficacy. n = 3. Unpaired *t-*test.\
\*\*p \< 0.02.\
CMV: Cytomegalovirus; RSV: Rous sarcoma virus.](btn-68-349-g2){#F2}

To examine whether the optimized virus packaging ratios improve target gene knockdown, we transduced cells with pLKO.1- and pLKO.1C-derived viruses carrying shRNA targeting *RB1* (sh*RB1*-733). Viruses generated from different ratios of viral components, promoters and packaging systems (as in [Figure 2](#F2){ref-type="fig"}A) were used to transduce DAOY cells and *RB1* mRNA quantitated by qRT-PCR \[[@B17]\] at 4 days post-transduction. Consistent with the viral titering results, third-generation packaging of pLKO.1C with 4:2:1:1 ratio resulted in the best *RB1* RNA knockdown ([Figure 2](#F2){ref-type="fig"}D).

To quantitate the improved virus production and titers enabled by pLKO.1C, we produced pLKO.1 and pLKO.1C versions of the sh*SCR*, sh*RB1-733* and sh*RB1-737* viruses using the optimized packaging ratios, and monitored viral p24 antigen concentration and viral titer by limiting dilution assay. After transduction of DAOY cells, twice as much p24 antigen and approximately ten-times higher virus titers were achieved with third-generation packaging and pLKO.1C compared with second-generation packaging with pLKO.1 ([Figure 3](#F3){ref-type="fig"}A--C). A similar higher transducing efficiency was observed with third-generation packaging and pLKO.1C in several additional cell lines ([Figure 3](#F3){ref-type="fig"}D). Although the ratios of sh*SCR*, sh*RB1-733* and sh*RB1-737* titers varied, optimized third-generation packaging of pLKO.1C-sh*SCR* consistently gave tenfold higher titers than second-generation packaging of pLKO.1. Taken together, introducing the CMV promoter into pLKO.1 greatly enhanced virus production, transduction and target gene knockdown using an optimized third-generation packaging system.

![High viral titers produced from pLKO.1C with optimal ratio of viral components.\
**(A--C)** pLKO.1 and pLKO.1C produced with optimized viral packaging construct ratios were used to transduce DAOY cells with second- or third- generation packaging, followed by assessment of viral p24 antigen (A) and viral titers (B & C) as described (Sigma Mission shRNA Manual). **(D)** Improved transduction efficiency of pLKO.1C evaluated with other cell lines. Values represent means of duplicate measurements and error bars the standard deviation. n = 2. Unpaired *t*-test.\
\*p \< 0.05; \*\*p \< 0.02; \*\*\*p \< 0.01.](btn-68-349-g3){#F3}

This study demonstrates a strategy to significantly improve lentiviral production with RSV-based lentiviral transfer vectors and third-generation viral packaging. The third-generation system expresses the minimal set of HIV-1 genes required to produce virus and omits *tat* because it is not required for promoter activity of transfer vectors that have chimeric CMV-HIV or RSV-HIV promoters \[[@B4],[@B8]\]. However, removal of Tat may decrease lentiviral vector RNA expression by decreasing transcriptional elongation through the HIV TAR element \[[@B13]\]. The higher production of pLKO.1C virus may primarily relate to the CMV promoter's strength in 293T cells \[[@B19]\] as the hybrid CMV--HIV promoter (like the RSV--HIV promoter) is likely to remain partially Tat-dependent \[[@B20]\]. Our data reveal that the viral yield and transducing efficiency of the third-generation packaging system were significantly improved by replacing the RSV promoter of pLKO.1 with the CMV promoter and optimizing the ratio of viral packaging components. We suggest that this is a robust method to improve transduction efficiency while retaining the significant biosafety features of the third-generation lentiviral packaging system.

pLKO.1C (with stuffer and PuroR), pLKO.1C-YFP (with stuffer and YFP), pLKO.1C-sh*SCR* and pLKO.1C-YFP-sh*SCR* have been deposited at AddGene.

MA1 vector was kindly provided by L Naldini of San Raffaele Telethon Institute for Gene Therapy. The authors thank D Shayler for contributing pLKO.1C-YFP.
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